Supernus Pharmaceuticals Q3 EPS $0.35 Beats $0.02 Estimate, Sales $226.771M Beat $215.917M Estimate
Benzinga Newsdesk 1 day ago
NewsEarningsEarnings Beats
Supernus Pharmaceuticals (NASDAQ:SUPN) reported quarterly earnings of $0.35 per share which beat the analyst consensus estimate of $0.02 by 1650 percent. This is a 143.75 percent increase over losses of $(0.80) per
Supernus Pharmaceuticals (NASDAQ:SUPN) reported quarterly earnings of $0.35 per share which beat the analyst consensus estimate of $0.02 by 1650 percent. This is a 143.75 percent increase over losses of $(0.80) per share from the same period last year. The company reported quarterly sales of $226.771 million which beat the analyst consensus estimate of $215.917 million by 5.03 percent. This is a 18.05 percent increase over sales of $192.103 million the same period last year.